Furthermore, we demonstrated the in vivo therapeutic potential of targeting ODF2L with siRNA-loaded LNPs combined with AZD1775 using the ovarian cancer ID8-Luc syngeneic mouse model. This evidence concerns the gene ODF2L and ovarian cancer.